Novartis completed about $25 billion of transactions in its product portfolios, including the sale of two units to British-based GlaxoSmithKline. Hester Plumridge explains why the Swiss company is ... more 
Novartis completed about $25 billion of transactions in its product portfolios, including the sale of two units to British-based GlaxoSmithKline. Hester Plumridge explains why the Swiss company is doing these deals now and what this means for the pharmaceutical industry. less 
1 / 26
WSJ Live
Tue, Apr 22, 2014 8:49 AM EDT